drugset / Trial / NCT02002832
A Clinical Trial of Lurasidone in Treatment of Schizophrenia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double-blind, double-dummy, parallel- controlled, adjustable dose, non-inferiority and multicentre study designed to evaluate the efficacy and safety of lurasidone on schizophrenia for 6 weeks treatment, and to compare with risperidone.
Timeline
- Start
- 2013-12
- Primary completion
- 2015-04
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lurasidone | Small molecule | 40 mg | — |
| Subject | Lurasidone | Small molecule | 80 mg | — |
| Comparator | Risperidone | Other / unclassified | 2 mg | — |
| Comparator | Risperidone | Other / unclassified | 6 mg | — |